Ye et al. [27] observed that treatment with L-arginine, the substrate of NOS, attenuates the severity of hypertension in rats with chronic renal failure, whereas treatment with L-NG-nitroarginine methyl ester (L-NAME), a competitive inhibitor of NOS, causes accelerated hypertension. This evidence concerns the gene NOS1 and chronic kidney disease.